Evotec SE EVO
NASDAQ EVO
$1.69 -0.08 (-4.79%)
At close: Nov 6, 2026 · 4:00 PM EST

Evotec SE (EVO) Non-Current Deferred Revenue (2021 - 2022)

Updated

Evotec SE (EVO) posted Non-Current Deffered Revenue of -$205.8 million for the quarter ended Jun 30, 2022.

Analysis

Evotec SE (EVO) Non-Current Deferred Revenue (2021 - 2022) Analysis & Trends

As of Dec 31, 2021, Evotec SE's Non-Current Deffered Revenue came in at -$39.62 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Iqvia Holdings 44.71 Bn 35.96 Bn 1.50 Bn
2 Medpace Holdings 18.26 Bn 15.91 Bn 223.89 Mn
3 Charles River Laboratories International 16.16 Bn 15.36 Bn 357.87 Mn
4 Icon 16.06 Bn 12.83 Bn 491.83 Mn
5 Fortrea Holdings 2.10 Bn 1.39 Bn 139.50 Mn
6 Ginkgo Bioworks Holdings 699.49 Mn -62.59 Mn 18.44 Mn
7 Evotec SE 601.99 Mn -1.16 Bn -
8 Champions Oncology 66.71 Mn 41.80 Mn 7.70 Mn
9 MindWalk Holdings 48.93 Mn 12.59 Mn 1.61 Mn
10 Natural Alternatives International 6.57 Mn -21.51 Mn 1.73 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2022 -201.48 Mn
Dec 31, 2021 -37.91 Mn
API Access

Evotec SE Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=EVO&period=max&api_key=YOUR_API_KEY